164070-40-0

Upstream product

• 145840-43-3 3,4,6-tri-O-acetyl-2-azido-2-deoxy-D-glucopyranosyl trichloroacetimidate 
• 153996-48-6 2,3:4,5-di-O-cyclohexylidene-1-O-(1R)-menthyloxycarbonyl-D-myo-inositol 
• 94715-56-7 3,4,6-tri-O-acetyl-2-azido-2-deoxy-α-D-glucopyranosyl trichloroacetimidate 

Downstream Products

• 202812-14-4 O-(2-azido-2-deoxy-α-D-glucopyranosyl)-(1->6)-2,3:4,5-di-O-cyclohexylidene-1-O-(1R)-menthyloxycarbonyl-D-myoinositol 
• 202812-15-5 C₅₆H₇₃N₃O₁₂ 
• 164070-36-4 O-(2-azido-6-O-benzoyl-3-O-benzyl-2-deoxy-α-D-glucopyranosyl)-(1->6)-2,3:4,5-di-O-cyclohexylidene-1-O-(1R)-menthyloxycarbonyl-D-myoinositol 
• 879126-32-6 C₄₄H₆₃N₃O₁₃ 

Relevant academic research and scientific papers

The chemical synthesis of bioactive glycosylphosphatidylinositols from Trypanosoma cruzi containing an unsaturated fatty acid in the lipid

(Chemical Equation Presented) Protection strategy: Glycosylphosphatidylinositols (GPIs) from the Trypanosoma cruzi parasite (a causative agent of Chagas' disease) that contain an unsaturated fatty acid in the lipid moiety (see partial structure of 1, R = (CH2) 7CH=CH-(CH2)7CH3, and 2, R = (CH2)7CH= CHCH2CH=CH(CH2) 4CH3) were prepared by a strategy that employs non-benzyl-type protecting groups. The synthetic GPIs show similar biological activity to their natural counterparts.